Saturday, September 5, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· May 18, 2026

Is It Time To Reconsider Salesforce (CRM) After This Year’s 32% Share Price Slide?

View original at finance.yahoo.com
“The latest twelve month free cash flow is about $14.27b.”
Verbatim excerpt from the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Salesforce's -40.0% return over the last year is lagging behind its peers

    60% confidence

  • Salesforce holds a valuation score of 5 out of 6

    60% confidence

  • Salesforce DCF analysis estimates intrinsic value at approximately $346.09 per share, implying the stock trades at a 49.9% discount and is undervalued

    60% confidence

  • Salesforce's trailing twelve month free cash flow is approximately $14.27 billion

    60% confidence

  • Analyst estimates project Salesforce free cash flow will reach approximately $19.85 billion by 2031

    60% confidence

Data points we hold from this source

Salesforce · cash14.27 USD
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Capital Surge Meets Investor Caution: Record Funding Rounds and Government Contracts Amid Valuation Skepticism
A single-week cluster of large AI/fintech funding rounds (Socure, Stability AI, Emerald AI, Generalist AI, Instinct, Gatik, Regent Craft) shows venture capital still pouring into AI infrastructure, identity, and autonomy plays, while Palantir's Army TITAN contract win coincided with a 6% stock drop — signaling that even flagship AI-defense revenue isn't immune to market reassessment of AI valuations. Efficiency-focused innovations like Multiverse Computing's model compression suggest the sector is also pivoting toward cost/inference economics as capital intensity draws scrutiny.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Morgan Stanley & Co. LLC
The same metric (eps) for the same entity (Morgan Stanley & Co. LLC) reported for the identical fiscal period (Q1 2026) and observation date (2026-03-31) has two conflicting values: 3.43 USD_per_share vs 3.08 USD. This is not a temporal change — both observations claim to measure the same point in time. The ~10% discrepancy (0.35 USD difference) is material for a financial metric.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,981
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,981 facts checked against source5,273 source documents archived
Query this data → isubstrate.com
Is It Time To Reconsider Salesforce (CRM) After This Year’s 32% Share Price Slide? — Source | Via News | Via News